| Not Yet Recruiting | SKB103 for Injection in Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2026-04-30 |
| Not Yet Recruiting | SKB105 for Injection in Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2026-04-01 |
| Recruiting | A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants Atopic Dermatitis | Phase 1 | 2026-03-31 |
| Not Yet Recruiting | Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoad Non-Small Cell Lung Cancer | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small C Non-small Lung Cancer | Phase 2 | 2026-02-01 |
| Recruiting | SKB500 Combinations in Patients With Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2026-01-30 |
| Recruiting | A Phase II Study of SKB571 in Patients With Lung Cancer Lung Cancer (Non-Small Cell) | Phase 2 | 2026-01-19 |
| Not Yet Recruiting | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma Thymic Carcinoma | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in O Ovarian Epithelial Cancer | Phase 2 | 2026-01-01 |
| Recruiting | A Study of SKB518 in Patients With Lung Cancer Lung Carcinoma | Phase 2 | 2025-08-29 |
| Recruiting | A Study of SKB107 in Advanced Solid Tumors With Bone Metastases Metastatic Solid Tumors | Phase 1 | 2025-08-15 |
| Recruiting | A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Metastatic Breast Cancer | Phase 3 | 2025-07-18 |
| Recruiting | SKB445 for Injection in Solid Tumors Advanced Solid Tumors | Phase 1 | 2025-02-05 |
| Recruiting | A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors Solid Malignancies | Phase 1 | 2024-12-17 |
| Recruiting | A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advan Advanced Solid Tumors | Phase 1 | 2024-12-13 |
| Recruiting | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Inj Advanced Solid Tumors | Phase 1 | 2024-12-12 |
| Recruiting | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Non-Small Cell Lung Cancer | Phase 3 | 2024-11-27 |
| Recruiting | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as F Non-Small Cell Lung Cancer | Phase 3 | 2024-10-30 |
| Recruiting | A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Her 2 Positive Breast Cancer | Phase 2 | 2024-09-20 |
| Recruiting | A Study of SKB518 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2024-07-04 |
| Active Not Recruiting | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Non-Small Cell Lung Cancer | Phase 3 | 2024-06-07 |
| Recruiting | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metasta Triple Negative Breast Cancer | Phase 3 | 2024-02-28 |
| Recruiting | Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Metastatic Breast Cancer | Phase 3 | 2023-10-31 |
| Active Not Recruiting | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic HER2-positive Breast Cancer | Phase 3 | 2023-07-18 |
| Active Not Recruiting | A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients Non-small Cell Lung Cancer | Phase 3 | 2023-06-26 |
| Completed | A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2022-08-30 |
| Active Not Recruiting | SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer Triple-negative Breast Cancer and HR+/HER2- BC | Phase 2 | 2022-08-17 |
| Active Not Recruiting | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-n Triple Negative Breast Cancer | Phase 3 | 2022-06-10 |
| Active Not Recruiting | KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine i Nasopharyngeal Carcinoma, Recurrent or Metastatic | Phase 3 | 2022-06-07 |
| Completed | A Study of KL340399 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2022-06-07 |
| Recruiting | A Study of SKB315 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2022-03-16 |
| Active Not Recruiting | A Study of KL590586 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2021-09-15 |
| Completed | Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment Metastatic Colorectal Cancer | Phase 3 | 2020-12-31 |
| Completed | KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma, Recurrent or Metastatic | Phase 2 | 2019-03-06 |
| Active Not Recruiting | A Study of A166 in Patients With Advanced Solid Malignant Tumors Breast Cancer | Phase 1 | 2018-08-09 |
| Completed | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Re Classical Hodgkin Lymphoma | Phase 2 | 2018-08-01 |